Leqembi (lecanemab), a monoclonal antibody that binds to beta-amyloid protofibrils, was approved by the US Food and Drug Administration for Alzheimer’s disease on 6 July, the first drug to show clinical benefit in patients with a mild stage of the disease. The full approval comes six months after Leqembi was given an accelerated authorisation on 6 January which was based on a surrogate endpoint – reducing amyloid plaques in the brain.
